Patents by Inventor Chun Jeih Ryu

Chun Jeih Ryu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-TM4SF4 HUMANIZED ANTIBODY AND USE THEREOF
    Publication number: 20240288436
    Abstract: The present invention relates to an anti-TM4SF4 (TransMembrane 4 Superfamily Member 4) humanized antibody and use thereof. The anti-TM4SF4 humanized antibody of present invention has high affinity for binding specifically to TM4SF4 while exhibiting low immunogenicity in humans, and thus can be advantageously used to detect TM4SF4 or to target cancer cells and cancer stem cells that overexpress TM4SF4.
    Type: Application
    Filed: June 16, 2022
    Publication date: August 29, 2024
    Applicants: KOREA ATOMIC ENERGY RESEARCH INSTITUTE, INDUSTRY ACADEMY COOPERATION FOUNDATION OF SEJONG UNIVERSITY
    Inventors: In Gyu KIM, Chun Jeih RYU, Min Kyu KIM, Rae Kwon KIM, Hwangseo PARK, Mun Ju CHOI, Yeon Jee KAHM, Byung Chul SHIN, U Hee JUNG
  • ANTI-TM4SF4 ANTIBODY AND USES THEREOF
    Publication number: 20230002485
    Abstract: The present invention relates to novel antibodies or antigen-binding fragments thereof that specifically bind to TransMembrane 4 Superfamily Member 4 (TM4SF4). These antibodies or antigen-binding fragments thereof exhibit proliferation inhibitory activity of cancer cells so as to effectively prevent or treat cancer, and reduce the self-renewal ability of cancer stem cells to be usefully used even in the treatments of cancer with a poor prognosis in conventional anticancer treatments.
    Type: Application
    Filed: December 4, 2020
    Publication date: January 5, 2023
    Inventors: In Gyu KIM, Rae Kwon KIM, Jai Ha LEE, Chang Kyu HEO, Yeon Jee KAHM, Byung Chul SHIN, Eun Wie CHO, Chun Jeih RYU, Min Kyu KIM, Mun Ju CHOI
  • Humanized antibody specific for surface antigen pre-S1 of HBV and preparation method thereof
    Patent number: 7115723
    Abstract: The present invention relates to humanized antibodies specific for HBV surface antigen pre-S1, which show binding affinity similar to mouse monoclonal antibody and which show remarkably reduced immunogenicity since they have less mouse-derived amino acid residues. Thus, the humanized antibodies of the present invention may be useful for the prevention of HBV infection and for the treatment of hepatitis B.
    Type: Grant
    Filed: November 19, 1999
    Date of Patent: October 3, 2006
    Assignees: Korea Institute of Science and Technology, Korea Green Cross Corporation
    Inventors: Hyo Jeong Hong, Chun Jeih Ryu, Hyangsuk Hur